A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2016
Price : $35 *
At a glance
- Drugs Pegargiminase (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Polaris Pharmaceuticals
- 02 Mar 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 17 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov record.
- 17 Nov 2015 Planned End Date changed from 1 Aug 2016 to 1 May 2016, as reported by ClinicalTrials.gov record.